Trials / Completed
CompletedNCT03973151
Study of HL-085 in NRAS Mutant Advanced Melanoma
A Phase I/II, Single Arm, Dose Escalation and Cohort Expansion Study to Evaluate Safety, Preliminary Efficacy of HL-085 in Patients With NRAS Mutant Advanced Melanoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Shanghai Kechow Pharma, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase I/II, open-label, dose escalation study to evaluate tolerability, safety, pharmacokinetics and efficacy in patients with NRAS mutant advanced melanoma .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HL-085 | HL-085 is one MEK inhibitor. |
Timeline
- Start date
- 2017-09-01
- Primary completion
- 2021-01-18
- Completion
- 2021-01-18
- First posted
- 2019-06-04
- Last updated
- 2023-05-31
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03973151. Inclusion in this directory is not an endorsement.